431 related articles for article (PubMed ID: 27746284)
21. A 3-plex methylation assay combined with the FGFR3 mutation assay sensitively detects recurrent bladder cancer in voided urine.
Kandimalla R; Masius R; Beukers W; Bangma CH; Orntoft TF; Dyrskjot L; van Leeuwen N; Lingsma H; van Tilborg AA; Zwarthoff EC
Clin Cancer Res; 2013 Sep; 19(17):4760-9. PubMed ID: 23842048
[TBL] [Abstract][Full Text] [Related]
22. Performance of the Bladder EpiCheck™ Methylation Test for Patients Under Surveillance for Non-muscle-invasive Bladder Cancer: Results of a Multicenter, Prospective, Blinded Clinical Trial.
Witjes JA; Morote J; Cornel EB; Gakis G; van Valenberg FJP; Lozano F; Sternberg IA; Willemsen E; Hegemann ML; Paitan Y; Leibovitch I
Eur Urol Oncol; 2018 Sep; 1(4):307-313. PubMed ID: 31100252
[TBL] [Abstract][Full Text] [Related]
23. Development of a 90-Minute Integrated Noninvasive Urinary Assay for Bladder Cancer Detection.
Wallace E; Higuchi R; Satya M; McCann L; Sin MLY; Bridge JA; Wei H; Zhang J; Wong E; Hiar A; Mach KE; Scherr D; Egerdie RB; Ohta S; Sexton WJ; Meng MV; Weizer AZ; Woods M; Jansz GK; Zadra J; Lotan Y; Goldfarb B; Liao JC
J Urol; 2018 Mar; 199(3):655-662. PubMed ID: 29061538
[TBL] [Abstract][Full Text] [Related]
24. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.
Allory Y; Beukers W; Sagrera A; Flández M; Marqués M; Márquez M; van der Keur KA; Dyrskjot L; Lurkin I; Vermeij M; Carrato A; Lloreta J; Lorente JA; Carrillo-de Santa Pau E; Masius RG; Kogevinas M; Steyerberg EW; van Tilborg AA; Abas C; Orntoft TF; Zuiverloon TC; Malats N; Zwarthoff EC; Real FX
Eur Urol; 2014 Feb; 65(2):360-6. PubMed ID: 24018021
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic predictive value of the Bladder EpiCheck test in the follow-up of patients with non-muscle-invasive bladder cancer.
Trenti E; D'Elia C; Mian C; Schwienbacher C; Hanspeter E; Pycha A; Kafka M; Degener S; Danuser H; Roth S; Pycha A
Cancer Cytopathol; 2019 Jul; 127(7):465-469. PubMed ID: 31154670
[TBL] [Abstract][Full Text] [Related]
26. Carbonic anhydrase IX as a diagnostic urinary marker for urothelial bladder cancer.
de Martino M; Lucca I; Mbeutcha A; Wiener HG; Haitel A; Susani M; Shariat SF; Klatte T
Eur Urol; 2015 Oct; 68(4):552-4. PubMed ID: 26138037
[TBL] [Abstract][Full Text] [Related]
27. Detection of multiple mutations in urinary exfoliated cells from male bladder cancer patients at diagnosis and during follow-up.
Critelli R; Fasanelli F; Oderda M; Polidoro S; Assumma MB; Viberti C; Preto M; Gontero P; Cucchiarale G; Lurkin I; Zwarthoff EC; Vineis P; Sacerdote C; Matullo G; Naccarati A
Oncotarget; 2016 Oct; 7(41):67435-67448. PubMed ID: 27611947
[TBL] [Abstract][Full Text] [Related]
28. Fibroblast growth factor receptor 3 mutation analysis on voided urine for surveillance of patients with low-grade non-muscle-invasive bladder cancer.
Zuiverloon TC; van der Aa MN; van der Kwast TH; Steyerberg EW; Lingsma HF; Bangma CH; Zwarthoff EC
Clin Cancer Res; 2010 Jun; 16(11):3011-8. PubMed ID: 20404005
[TBL] [Abstract][Full Text] [Related]
29. Hematuria screening test for urinary bladder mucosal infiltration in cervical cancer.
Chuttiangtum A; Udomthavornsuk B; Chumworathayi B
Asian Pac J Cancer Prev; 2012; 13(10):4931-3. PubMed ID: 23244084
[TBL] [Abstract][Full Text] [Related]
30. A noninvasive urine-based methylation biomarker panel to detect bladder cancer and discriminate cancer grade.
Hermanns T; Savio AJ; Olkhov-Mitsel E; Mari A; Wettstein MS; Saba K; Bhindi B; Kuk C; Poyet C; Wild PJ; Noon A; Bashir S; Juvet T; Rendon RA; Waltregny D; van der Kwast T; Finelli A; Kulkarni GS; Fleshner NE; Lo K; Bapat B; Zlotta AR
Urol Oncol; 2020 Jun; 38(6):603.e1-603.e7. PubMed ID: 32081560
[TBL] [Abstract][Full Text] [Related]
31. Gene expression test for the non-invasive diagnosis of bladder cancer: A prospective, blinded, international and multicenter validation study.
Ribal MJ; Mengual L; Lozano JJ; Ingelmo-Torres M; Palou J; Rodríguez-Faba O; Witjes JA; Van der Heijden AG; Medina R; Conde JM; Marberger M; Schmidbauer J; Fernández PL; Alcaraz A
Eur J Cancer; 2016 Feb; 54():131-138. PubMed ID: 26761785
[TBL] [Abstract][Full Text] [Related]
32. A multigene urine test for the detection and stratification of bladder cancer in patients presenting with hematuria.
O'Sullivan P; Sharples K; Dalphin M; Davidson P; Gilling P; Cambridge L; Harvey J; Toro T; Giles N; Luxmanan C; Alves CF; Yoon HS; Hinder V; Masters J; Kennedy-Smith A; Beaven T; Guilford PJ
J Urol; 2012 Sep; 188(3):741-7. PubMed ID: 22818138
[TBL] [Abstract][Full Text] [Related]
33. Newly diagnosed bladder cancer: the relationship of initial symptoms, degree of microhematuria and tumor marker status.
Boman H; Hedelin H; Jacobsson S; Holmäng S
J Urol; 2002 Nov; 168(5):1955-9. PubMed ID: 12394684
[TBL] [Abstract][Full Text] [Related]
34. MALBAC-based chromosomal imbalance analysis: a novel technique enabling effective non-invasive diagnosis and monitoring of bladder cancer.
Liu H; He W; Wang B; Xu K; Han J; Zheng J; Ren J; Shao L; Bo S; Lu S; Lin T; Huang J
BMC Cancer; 2018 Jun; 18(1):659. PubMed ID: 29907142
[TBL] [Abstract][Full Text] [Related]
35. A urinary assay for mutation and methylation biomarkers in the diagnosis and recurrence prediction of non-muscle invasive bladder cancer patients.
Huang H; Liu A; Liang Y; Xin Y; Liu J; Hao Y; Huang D; Chen L; Li W; Jiang G; Huang Y; Xu Y; Zhang J; Ma T; Xu D; Gao Y
BMC Med; 2023 Sep; 21(1):357. PubMed ID: 37726806
[TBL] [Abstract][Full Text] [Related]
36. A segregation index combining phenotypic (clinical characteristics) and genotypic (gene expression) biomarkers from a urine sample to triage out patients presenting with hematuria who have a low probability of urothelial carcinoma.
Kavalieris L; O'Sullivan PJ; Suttie JM; Pownall BK; Gilling PJ; Chemasle C; Darling DG
BMC Urol; 2015 Mar; 15():23. PubMed ID: 25888331
[TBL] [Abstract][Full Text] [Related]
37. Filtration Device for On-Site Collection, Storage and Shipment of Cells from Urine and Its Application to DNA-Based Detection of Bladder Cancer.
Andersson E; Dahmcke CM; Steven K; Larsen LK; Guldberg P
PLoS One; 2015; 10(7):e0131889. PubMed ID: 26151138
[TBL] [Abstract][Full Text] [Related]
38. Use of a multitarget fluorescence in situ hybridization assay to diagnose bladder cancer in patients with hematuria.
Sarosdy MF; Kahn PR; Ziffer MD; Love WR; Barkin J; Abara EO; Jansz K; Bridge JA; Johansson SL; Persons DL; Gibson JS
J Urol; 2006 Jul; 176(1):44-7. PubMed ID: 16753364
[TBL] [Abstract][Full Text] [Related]
39. Detection of urothelial bladder cancer cells in voided urine can be improved by a combination of cytology and standardized microsatellite analysis.
Wild PJ; Fuchs T; Stoehr R; Zimmermann D; Frigerio S; Padberg B; Steiner I; Zwarthoff EC; Burger M; Denzinger S; Hofstaedter F; Kristiansen G; Hermanns T; Seifert HH; Provenzano M; Sulser T; Roth V; Buhmann JM; Moch H; Hartmann A
Cancer Epidemiol Biomarkers Prev; 2009 Jun; 18(6):1798-806. PubMed ID: 19454613
[TBL] [Abstract][Full Text] [Related]
40. Identification and validation of the methylated TWIST1 and NID2 genes through real-time methylation-specific polymerase chain reaction assays for the noninvasive detection of primary bladder cancer in urine samples.
Renard I; Joniau S; van Cleynenbreugel B; Collette C; Naômé C; Vlassenbroeck I; Nicolas H; de Leval J; Straub J; Van Criekinge W; Hamida W; Hellel M; Thomas A; de Leval L; Bierau K; Waltregny D
Eur Urol; 2010 Jul; 58(1):96-104. PubMed ID: 19674832
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
